About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

MELBOURNE, Australia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing treatments for recurring and metastatic cancer, announced its fiscal year-end update following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025. The reporting period concluded on June 30, 2025.

As a result of significant changes to its financial position during the year, the Company was able to complete an initial public offering and uplisting to Nasdaq on August 14, 2025. These developments are expected to support future operational and research activities. James Nathanielsz, Propanc’s CEO stated, “The Company is focused on advancing our lead therapeutic candidate and further building our intellectual property portfolio with various development milestones anticipated by the end of 2025 and throughout 2026. We are also actively engaged in collaborative efforts with regards to our clinical pipeline.” Mr. Nathanielsz concludes, “In addition, we intend to create a $100 Million or greater, digital asset treasury over the next twelve months. As of late 2025, there are over 200 public companies holding digital assets in their treasuries, with estimates ranging from over 150 to more than 200 firms. These Digital Asset Treasury Companies (DATs) hold billions of dollars in cryptocurrencies, primarily Bitcoin, but increasingly also Ethereum, Solana, and other altcoins, as a strategic corporate asset per Morningstar.”

Key financial data from the Company’s filing on June 30, 2025, includes:

  • Total assets increased from over $72,000 to $19.6 Million.
  • The growth in assets is primarily attributed to prepaid service contracts related to market awareness, advisory, accounting, finance, manufacturing, and R&D activities.
  • Stockholders’ equity rose to $13.9 Million from a deficit of $3.8 Million.

Following the NASDAQ uplisting, Propanc entered into an underwriting agreement with D Boral Capital and completed an offering of 1,000,000 common shares generating gross proceeds of $4 Million.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.

The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.95
+0.00 (0.00%)
AAPL  258.45
+0.00 (0.00%)
AMD  230.23
+0.00 (0.00%)
BAC  51.10
+0.00 (0.00%)
GOOG  252.53
+0.00 (0.00%)
META  733.41
+0.00 (0.00%)
MSFT  520.54
+0.00 (0.00%)
NVDA  180.28
+0.00 (0.00%)
ORCL  272.66
+0.00 (0.00%)
TSLA  438.97
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.